

**ALS2 Antibody (C-term) Blocking Peptide**  
**Synthetic peptide**  
**Catalog # BP6501b****Specification**

---

**ALS2 Antibody (C-term) Blocking Peptide - Product Information**

Primary Accession [Q96Q42](#)

**ALS2 Antibody (C-term) Blocking Peptide - Additional Information**

**Gene ID** 57679

**Other Names**

Alsin, Amyotrophic lateral sclerosis 2 chromosomal region candidate gene 6 protein, Amyotrophic lateral sclerosis 2 protein, ALS2, ALS2CR6, KIAA1563

**Target/Specificity**

The synthetic peptide sequence used to generate the antibody [AP6501b](/products/AP6501b) was selected from the C-term region of human ALS2. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

**Format**

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

**Storage**

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

**Precautions**

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

**ALS2 Antibody (C-term) Blocking Peptide - Protein Information**

**Name** ALS2

**Synonyms** ALS2CR6, KIAA1563

**Function**

May act as a GTPase regulator. Controls survival and growth of spinal motoneurons (By similarity).

**ALS2 Antibody (C-term) Blocking Peptide - Protocols**

Provided below are standard protocols that you may find useful for product applications.

- [Blocking Peptides](#)

**ALS2 Antibody (C-term) Blocking Peptide - Images****ALS2 Antibody (C-term) Blocking Peptide - Background**

ALS2 contains an ATS1/RCC1-like domain, a RhoGEF domain, and a vacuolar protein sorting 9 (VPS9) domain, all of which are guanine-nucleotide exchange factors that activate members of the Ras superfamily of GTPases. The protein functions as a guanine nucleotide exchange factor for the small GTPase RAB5. The protein localizes with RAB5 on early endosomal compartments, and functions as a modulator for endosomal dynamics. Mutations in its gene result in several forms of juvenile lateral sclerosis and infantile-onset ascending spastic paralysis.

**ALS2 Antibody (C-term) Blocking Peptide - References**

Soares,D.C., J Mol Model 15 (2), 113-122 (2009)Mintchev,N., Neurology 72 (1), 28-32 (2009)